App-Quantinova.ai

Response to cardiac resynchronisation therapy is associated with reduction in serum parathyroid hormone level

Mark Mills - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Parathyroid hormone

Cardiac sarcoidosis: the outcomes of patients undergoing cardiac transplant

Syed Gardezi - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Cardiac sarcoidosis

N/A

The role of cardiopulmonary exercise testing in patients undergoing heart transplantation

Nikhil Chatrath - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Infectious Diseases (ID)

Tuberculosis

N/A

Heart failure admissions and device therapy provision during the covid-19 pandemic

Rimma Hall - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congenital heart disease

N/A

Designing an educational app for patients with heart failure

Arvind Singhal - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Avatar

One year outcomes of heart failure multispecialty multidisciplinary team virtual meetings

Hani essa - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Development of outpatient based acute heart failure care calls for development of clinical psychology service for whole-person care provision in the UK

ABDULLAH ABDULLAH - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

Hydroxyzine

Lancashire objective volume evaluation of leg oedema in heart failure randomized controlled cross-over trials (love-HF artificial intelligence research programme): rationale and methodology

Reham Awad - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

furosemide GR

An improved ejection fraction parameter capable of representing cardiac function regardless of heart morphology to distinguish hfpef from normal hearts

Choon Hwai Yap - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

What actually happens in a specialist heart failure clinic?

Arvind Singhal - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Systolic dysfunction

N/A

Is a dedicated HFpEF clinic effective in managing patients with heart failure with preserved fraction (HFpEF)?

Patrick Tran - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Applicability of use of sodium- glucose co-transporter-2 inhibitors (SGLT2i) in patients with heart failure with reduced ejection fraction (HFrEF) at London northwest university heathcare NHS trust

Oltiana Lakra - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart failure with reduced ejection fraction

EF-40

What happens to patients coded heart failure and discharged from the emergency department

Jan Oliver - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Heart muscle disease

N/A

A novel ultrasound based method for screening for heart failure

Anenta Ramakrishnan - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Patient flow through a specialist heart failure clinic: a time and motion study

Arvind Singhal - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Estimations of plasma volume status in patients with chronic heart failure: a useful tool for diagnosing and treating congestion?

Joe Cuthbert - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Systolic dysfunction

N/A

A single centre study assessing the effectiveness of active monitoring, using telemedicine, in preventing heart failure admissions and death in a primary care population with systolic heart failure

Nicola Bowers - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Systolic dysfunction

N/A

Investigating the direct implications of the dapa HF trial and the indroducton of sodium-glucose like co-transporter 2 (SGLT2) inhibitors on middlesbrough’s heart failure population

Samuel Richardson - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Type 1 diabetes mellitus

Dapagliflozin

NHS test bed project: monitoring of heart failure patients in the COVID-19 pandemic

Kajaluxy Ananthan - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Daily weight and fluid balance assessment in patients admitted with acute heart failure

Norildin Al-Refaie - British Cardiovascular Society (BCS) , 2021

Therapeutic Area

Disease

Drug/Treatment

Cardiovascular (CVS)

Congestive heart failure

N/A

Filters

45280 Abstracts